27-Hydroxycholesterol Promotes Cell-Autonomous, ER-Positive Breast Cancer Growth

Autor: Qian Wu, Tomonori Ishikawa, Rosa Sirianni, Hao Tang, Jeffrey G. McDonald, Ivan S. Yuhanna, Bonne Thompson, Luc Girard, Chieko Mineo, Rolf A. Brekken, Michihisa Umetani, David M. Euhus, Yang Xie, Philip W. Shaul

Publikováno v: Cell Reports, Vol 5, Iss 3, Pp 637-645 (2013)

To date, estrogen is the only known endogenous estrogen receptor (ER) ligand that promotes ER+ breast tumor growth. We report that the cholesterol metabolite 27-hydroxycholesterol (27HC) stimulates MCF-7 cell xenograft growth in mice. More importantl

Externí odkaz: https://doaj.org/article/9d756b405b124e4b8b9ed533e3615b9a

Data from RASSF1A Polymorphism A133S Is Associated with Early Onset Breast Cancer in BRCA1/2 Mutation Carriers

Autor: John D. Minna, Gail E. Tomlinson, David M. Euhus, Judy E. Garber, Olufunmilayo I. Olopade, Bifeng Zhang, Aihua Bian, Cheryl M. Lewis, Tina T-L. Chen, David S. Shames, Chunxian Huang, Xian-Jin Xie, Boning Gao

The tumor suppressor gene RASSF1A regulates cell cycle progression, apoptosis, and microtubule stability and is inactivated by promoter methylation in ∼50% of breast cancers. It has been shown previously that the polymorphism A133S in RASSF1A reduc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a86076c87d7b01e9621afe78cf68e956
https://doi.org/10.1158/0008-5472.c.6496488

Breast cancer progression when definitive surgery is delayed

Autor: Ziad Alaidy, Ahmed S. Mohamed, David M. Euhus

Publikováno v: The Breast Journal

Deferment of definitive surgery for some breast cancers has been proposed as a way to conserve hospital resources during the COVID-19 pandemic. However, it is currently unknown which, if any, breast cancers are capable of progressing during a few to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67745ec77ae87dcae70d737cfe6bb768
https://doi.org/10.1111/tbj.14177

Legacy Genetic Testing Results for Cancer Susceptibility: How Common are Conflicting Classifications in a Large Variant Dataset from Multiple Practices?

Autor: David P. Ondrula, Kevin S. Hughes, David M. Euhus, John F. Sandbach, S. Dwight Lyons, Yuxi Liu, Alan Semine, Melford Allan C. Lazarte, Linda Ann Smith, Kanhua Yin, Linsey Gold, Gayle Patel, Danielle Braun, Basanta Lamichhane, Eric J. Brown, Pat Whitworth, Richard H. Kanak, Gia Compagnoni, Giovanni Parmigiani, Barry Rosen, Colleen App

Publikováno v: Annals of Surgical Oncology. 27:2212-2220

The classification of germline variants may differ between labs and change over time. We apply a variant harmonization tool, Ask2Me VarHarmonizer, to map variants to ClinVar and identify discordant variant classifications in a large multipractice var

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f088448d8997f1e6fb79b66ea5827fd
https://doi.org/10.1245/s10434-020-08492-9

Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer:a multicentre pooled analysis of 5161 patients

Autor: Christina Yau, Marie Osdoit, Marieke van der Noordaa, Sonal Shad, Jane Wei, Diane de Croze, Anne-Sophie Hamy, Marick Laé, Fabien Reyal, Gabe S Sonke, Tessa G Steenbruggen, Maartje van Seijen, Jelle Wesseling, Miguel Martín, Maria del Monte-Millán, Sara López-Tarruella, Judy C Boughey, Matthew P Goetz, Tanya Hoskin, Rebekah Gould, Vicente Valero, Stephen B Edge, Jean E Abraham, John M S Bartlett, Carlos Caldas, Janet Dunn, Helena Earl, Larry Hayward, Louise Hiller, Elena Provenzano, Stephen-John Sammut, Jeremy S Thomas, David Cameron, Ashley Graham, Peter Hall, Lorna Mackintosh, Fang Fan, Andrew K Godwin, Kelsey Schwensen, Priyanka Sharma, Angela M DeMichele, Kimberly Cole, Lajos Pusztai, Mi-Ok Kim, Laura J van 't Veer, Laura J Esserman, W Fraser Symmans, Kathi Adamson, Kathy S. Albain, Adam L. Asare, Smita M. Asare, Ron Balassanian, Heather Beckwith, Scott M. Berry, Donald A. Berry, Judy C. Boughey, Meredith B. Buxton, Yunn-Yi Chen, Beiyun Chen, A. Jo Chien, Stephen Y. Chui, Amy S. Clark, Julia L. Clennell, Brian Datnow, Angela M. DeMichele, Xiuzhen Duan, Kirsten K. Edmiston, Anthony D. Elias, Erin D. Ellis, Laura L. Esserman, David M. Euhus, Oluwole Fadare, Michael D Feldman, Andres Forero-Torres, Barbara B. Haley, Hyo S. Han, Shuko Harada, Patricia Haugen, Teresa Helsten, Gillian L. Hirst, Nola M. Hylton, Claudine Isaacs, Kathleen Kemmer, Qamar J. Khan, Laila Khazai, Molly E. Klein, Gregor Krings, Julie E. Lang, Lauren G. LeBeau, Brian Leyland-Jones, Minetta C. Liu, Shelly Lo, Janice Lu, Anthony Magliocco, Jeffrey B. Matthews, Michelle E. Melisko, Paulette Mhawech-Fauceglia, Stacy L. Moulder, Rashmi K. Murthy, Rita Nanda, Donald W. Northfelt, Idris T. Ocal, Olufunmilayo Olopade, Stefan Pambuccian, Melissa Paoloni, John W. Park, Barbara A. Parker, Jane Perlmutter, Garry Peterson, Mara Rendi, Hope S. Rugo, Sunati Sahoo, Sharon Sams, Ashish Sanil, Husain Sattar, Richard B. Schwab, Ruby Singhrao, Katherine Steeg, Erica Stringer-Reasor, W. Fraser Symmans, Ossama Tawfik, Debasish Tripathy, Megan L. Troxell, Laura J. van't Veer, Sara J. Venters, Tuyethoa Vinh, Rebecca K. Viscusi, Anne M. Wallace, Shi Wei, Amy Wilson, Douglas Yee, Jay C. Zeck

Publikováno v: I-SPY 2 Trial Consortium 2022, ' Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer : a multicentre pooled analysis of 5161 patients ', The Lancet Oncology, vol. 23, no. 1, pp. 149-160 . https://doi.org/10.1016/S1470-2045(21)00589-1
The Lancet. Oncology, vol 23, iss 1
The Lancet Oncology, 23(1), 149-160. Lancet Publishing Group

Background: Previous studies have independently validated the prognostic relevance of residual cancer burden (RCB) after neoadjuvant chemotherapy. We used results from several independent cohorts in a pooled patient-level analysis to evaluate the rel

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9b5a03d8d05046179f5dcc364471bd0
https://research.vumc.nl/en/publications/4b35d135-33e6-4bf5-982e-dab0f5ddbfd8